Use of systemic antineoplastic drug therapy after regulatory agency approval

Oncology

Volumn 72, Issue 3-4, 2008, Pages 145-146

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; TOPOTECAN;

BREAST CANCER; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; EDITORIAL; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; SWITZERLAND; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; NEOPLASMS;

EID: 38549121323     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112730     Document Type: Editorial

References (10)

1. Salzberg M, Thürlimann B, Hasler U, et al: Pegylated liposomal doxorubicin (Caelyx®) in metastatic breast cancer: a community-based observation study. Oncology 2007;72:147-151.
2. Elting LS, Cooksley C, Bekele BN, et al: Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 2006;106:2452-2458.
3. Davis S, Wright PW, Schulman SF, et al: Participants in prospective, randomized clinical trials for non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 1985;56:1710-1718.
4. Hori A, Shibata T, Kami M, et al: Age disparity between a cancer population and participants in clinical trials submitted as a new drug application of anticancer drugs in Japan. Cancer 2007;109:2541-2546.
5. Campos SM, Penson RT, Mays AR, et al: The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001;81:206-212.
6. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000;78:369-372.
7. Rose PG, Maxson JH, Fusco, et al: Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 2001;82:323-328.
8. Levy T, Inbar M, Menczer J, et al: Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 2004;95:686-690.
9. Rodriguez M, Rose PG: Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001;83:257-262.
10. Gronlund B, Hansen HH, Hogdall C, et al: Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer 2002;95:1656-1662.